Literature DB >> 12917626

Characterization of the p53 mutants ability to inhibit p73 beta transactivation using a yeast-based functional assay.

Paola Monti1, Paola Campomenosi, Yari Ciribilli, Raffaella Iannone, Anna Aprile, Alberto Inga, Mitsuhiro Tada, Paola Menichini, Angelo Abbondandolo, Gilberto Fronza.   

Abstract

p53 is the most frequently altered tumor suppressor gene in a wide spectrum of human tumors. The large majority of p53 mutations observed in tumors are missense mutations. The p73 gene, encoding a protein with significant sequence similarity to p53, expresses multiple transcription-competent spliced variants, or transcription-incompetent forms (i.e. DeltaNp73). It was clearly shown that p73 transactivation from a p53-responsive promoter is inhibited by some tumor-derived p53 mutants in eucaryotic cells. In this study, we adapted a yeast-based p53 functional assay for the analysis of the influences of different p53 mutants on the activity of one of the p73 isoforms, namely p73beta. We determined the ability of a panel of 61 p53 mutants to inhibit p73beta activity following the net transcription of the ADE2 color (red/white) reporter gene driven by a p53-responsive promoter. By analysing a large number of mutants, we could conclude that interference: (a) is a quite frequent phenomenon (more than 70% of p53 mutants analysed are interfering); (b) is not confined to p53 mutations located in particular topological regions of the DNA binding domain; (c) does not appear to be dependent on the kind of side chains introduced at a specific position; (d) appears to significantly correlate with evolutionary conservation of the mutated p53 codon, frequency of occurrence of the mutation in tumors. The influence of a common R/P polymorphism at codon 72 on the ability of p53 mutants to interfere with p73beta was also studied. Two sets of polymorphic variants (R and P) for 14 mutants were constructed and analysed. In all cases, the R/P 72 polymorphism was phenotypically irrelevant. In conclusion, our results suggest that the interpretation of the biological effects of p53 mutants should take into consideration the possibility that p53 mutants show loss or gain of function also through the interference with p53 family members.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12917626     DOI: 10.1038/sj.onc.1206511

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  17 in total

1.  Structure of p73 DNA-binding domain tetramer modulates p73 transactivation.

Authors:  Abdul S Ethayathulla; Pui-Wah Tse; Paola Monti; Sonha Nguyen; Alberto Inga; Gilberto Fronza; Hector Viadiu
Journal:  Proc Natl Acad Sci U S A       Date:  2012-04-02       Impact factor: 11.205

2.  Homozygosity for Pro of p53 Arg72Pro as a potential risk factor for hepatocellular carcinoma in Chinese population.

Authors:  Zhong-Zheng Zhu; Wen-Ming Cong; Shu-Fang Liu; Hui Dong; Guan-Shan Zhu; Meng-Chao Wu
Journal:  World J Gastroenterol       Date:  2005-01-14       Impact factor: 5.742

3.  Serine substitution of proline at codon 151 of TP53 confers gain of function activity leading to anoikis resistance and tumor progression of head and neck cancer cells.

Authors:  Tong-Xin Xie; Ge Zhou; Mei Zhao; Daisuke Sano; Samar A Jasser; Richard G Brennan; Jeffrey N Myers
Journal:  Laryngoscope       Date:  2013-04-26       Impact factor: 3.325

4.  Clinical aspects of TP53 gene inactivation in diffuse large B-cell lymphoma.

Authors:  Elena N Voropaeva; Tatyana I Pospelova; Mikhail I Voevoda; Vladimir N Maksimov; Yuriy L Orlov; Olga B Seregina
Journal:  BMC Med Genomics       Date:  2019-03-13       Impact factor: 3.063

5.  A comparison of multiscale methods for the analysis of molecular dynamics simulations.

Authors:  Noah C Benson; Valerie Daggett
Journal:  J Phys Chem B       Date:  2012-04-24       Impact factor: 2.991

6.  The prevalence of germ-line TP53 mutations in women diagnosed with breast cancer before age 30.

Authors:  Ophira M Ginsburg; Mohammad R Akbari; Zeba Aziz; Robert Young; Henry Lynch; Parviz Ghadirian; Andre Robidoux; Julian Londono; Gonzalo Vasquez; Magda Gomes; Mauricio Magalhaes Costa; Constantine Dimitrakakis; Gustavo Gutierrez; Robert Pilarski; Robert Royer; Steven A Narod
Journal:  Fam Cancer       Date:  2009       Impact factor: 2.375

7.  Evaluation of p53 codon 72 polymorphism in adenocarcinomas of the colon and rectum in La Plata, Argentina.

Authors:  Luis Orlando Pérez; Martin Carlos Abba; Fernando Noel Dulout; Carlos Daniel Golijow
Journal:  World J Gastroenterol       Date:  2006-03-07       Impact factor: 5.742

8.  Analytical Validation and Application of a Targeted Next-Generation Sequencing Mutation-Detection Assay for Use in Treatment Assignment in the NCI-MPACT Trial.

Authors:  Chih-Jian Lih; David J Sims; Robin D Harrington; Eric C Polley; Yingdong Zhao; Michele G Mehaffey; Thomas D Forbes; Biswajit Das; William D Walsh; Vivekananda Datta; Kneshay N Harper; Courtney H Bouk; Lawrence V Rubinstein; Richard M Simon; Barbara A Conley; Alice P Chen; Shivaani Kummar; James H Doroshow; Paul M Williams
Journal:  J Mol Diagn       Date:  2015-11-18       Impact factor: 5.568

9.  Transcriptional functionality of germ line p53 mutants influences cancer phenotype.

Authors:  Paola Monti; Yari Ciribilli; Jennifer Jordan; Paola Menichini; David M Umbach; Michael A Resnick; Lucio Luzzatto; Alberto Inga; Gilberto Fronza
Journal:  Clin Cancer Res       Date:  2007-07-01       Impact factor: 12.531

10.  Transactivation specificity is conserved among p53 family proteins and depends on a response element sequence code.

Authors:  Yari Ciribilli; Paola Monti; Alessandra Bisio; H Thien Nguyen; Abdul S Ethayathulla; Ana Ramos; Giorgia Foggetti; Paola Menichini; Daniel Menendez; Michael A Resnick; Hector Viadiu; Gilberto Fronza; Alberto Inga
Journal:  Nucleic Acids Res       Date:  2013-07-26       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.